+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vivitrol"

Addictions Therapeutics Market Report 2025 - Product Thumbnail Image

Addictions Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Alcohol Use Disorder Market Report and Forecast 2025-2034 - Product Thumbnail Image

Alcohol Use Disorder Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Alcohol Use Disorder - Pipeline Insight, 2025 - Product Thumbnail Image

Alcohol Use Disorder - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Substance (Drug) Abuse Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Substance (Drug) Abuse Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Smoking Cessation Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Smoking Cessation Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
From
  • 11 Results (Page 1 of 1)
Loading Indicator

Vivitrol is a brand name for the injectable form of naltrexone, an opioid antagonist used to treat addiction disorders. It is used to treat alcohol and opioid dependence, and is administered once a month. Vivitrol works by blocking the effects of opioids, reducing cravings and preventing relapse. It is also used to treat opioid overdose. Vivitrol is an alternative to daily oral medications, and is often used in combination with counseling and other forms of therapy. Vivitrol is marketed by Alkermes, a biopharmaceutical company based in Dublin, Ireland. Other companies in the market include Indivior, a British pharmaceutical company, and Orexo, a Swedish pharmaceutical company. Show Less Read more